Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.640
+0.147 (9.85%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Calidi Biotherapeutics Employees
Calidi Biotherapeutics had 29 employees as of December 31, 2025. The number of employees increased by 1 or 3.57% compared to the previous year.
Employees
29
Change (1Y)
1
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
-$862,414
Market Cap
1.99M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 1 | 3.57% |
| Dec 31, 2024 | 28 | -13 | -31.71% |
| Dec 31, 2023 | 41 | 3 | 7.89% |
| Dec 31, 2022 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Virax Biolabs Group | 26 |
| Moleculin Biotech | 17 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| CDT Equity | 4 |
| GRI Bio | 4 |
| Creative Medical Technology Holdings | 4 |
| Oragenics | 3 |
CLDI News
- 6 days ago - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewsWire
- 12 days ago - Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewsWire
- 13 days ago - Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - GlobeNewsWire
- 25 days ago - Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - GlobeNewsWire
- 6 weeks ago - Calidi receives pre-IND regulatory feedback from FDA for CLD-401 - TheFly
- 6 weeks ago - Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - GlobeNewsWire